 Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. NASDAQ: RUBY was among the biggest gainers of the week after the biopharma reported positive Phase 12 data for its RTX-240 in solid tumors. 